Testing effectiveness (Phase 2)Study completedNCT01372410
What this trial is testing
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Who this might be right for
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline 163